{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:00:03Z","timestamp":1792080003967,"version":"4.4.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Plasma cell neoplasms (PCNs) harboring IGH::CCND3 (t(6;14)) are rare (&amp;lt;1% of PCNs). We sought to study these cases, as they have not been studied as a distinct entity, and their clinicopathologic features are not well characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cytogenetics databases were searched for positive IGH::CCND3 interphase fluorescence in situ hybridization (FISH) results in plasma cell neoplasms. We analyzed the clinical, morphologic, immunophenotypic, and cytogenetic features of these cases and evaluated the utility of cyclin D3 immunohistochemistry (IHC) for identifying these neoplasms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixteen patients were identified, presenting with multiple myeloma (n\u2009=\u20099), monoclonal gammopathy of undetermined significance (n\u2009=\u20093), smoldering myeloma (n\u2009=\u20092), plasma cell leukemia (n\u2009=\u20091), and amyloid light chain amyloidosis (n\u2009=\u20091). Median age at diagnosis was 68.9\u2009years. Most cases showed lymphoplasmacytoid morphology (63%, 10\/16), with frequent CD20 expression (53%, 8\/15) and aberrant expression of CD56 (71%, 10\/14) and CD117 (69%, 9\/13). Monosomy 13 was the most frequent concurrent cytogenetic abnormality (50%, 7\/14). Cyclin D3 IHC showed nuclear expression in plasma cells in all tested patients (11\/11). Background erythroid precursors and megakaryocytes also showed variable positivity. When performed as a dual immunostain with CD138, cyclin D3 served as a highly sensitive and specific method for detecting these neoplastic plasma cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IGH::CCND3 PCNs frequently exhibit lymphoplasmacytoid features and CD20 expression, resembling the more common t(11;14) PCNs. Cyclin D3 IHC is an effective surrogate for the t(6;14) translocation in PCNs. We recommend using cyclin D3 IHC in the workup of PCNs with lymphoplasmacytoid morphology but negative cyclin D1 to appropriately trigger reflex FISH testing in positive cases and rescue them from the \u201cpartner-negative\u201d category.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajcp\/aqag080","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:37:53Z","timestamp":1783532273000},"source":"Crossref","is-referenced-by-count":1,"title":["Clinicopathologic characterization of plasma cell neoplasms with\n                    <i>IGH<\/i>\n                    ::\n                    <i>CCND3<\/i>"],"prefix":"10.1093","volume":"166","author":[{"given":"Nandan","family":"Padmanabha","sequence":"first","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA,","place":["United States"]},{"name":"Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S","family":"Sperling","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA,","place":["United States"]},{"name":"Division of Hematology, Stanford University , Palo Alto, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3827-953X","authenticated-orcid":false,"given":"Phillip D","family":"Michaels","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA,","place":["United States"]},{"name":"Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Sadigh","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"2026070813374605800_aqag080-B1","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"2026070813374605800_aqag080-B2","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International Myeloma Society\/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026070813374605800_aqag080-B3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/leu.2017.179","article-title":"Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients","volume":"32","author":"Shah","year":"2018","journal-title":"Leukemia"},{"key":"2026070813374605800_aqag080-B4","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1101\/gad.1256504","article-title":"Living with or without cyclins and cyclin-dependent kinases","volume":"18","author":"Sherr","year":"2004","journal-title":"Genes Dev"},{"key":"2026070813374605800_aqag080-B5","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/s1535-6108(03)00301-5","article-title":"Requirement for cyclin D3 in lymphocyte development and T cell leukemias","volume":"4","author":"Sicinska","year":"2003","journal-title":"Cancer Cell"},{"key":"2026070813374605800_aqag080-B6","doi-asserted-by":"publisher","first-page":"11345","DOI":"10.1158\/0008-5472.CAN-05-2159","article-title":"Mutually exclusive cyclin-dependent kinase 4\/cyclin D1 and cyclin-dependent kinase 6\/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma","volume":"65","author":"Ely","year":"2005","journal-title":"Cancer Res"},{"key":"2026070813374605800_aqag080-B7","first-page":"2950","article-title":"Multiple myeloma with t(11; 14): unique biology and evolving landscape","volume":"12","author":"Bal","year":"2022","journal-title":"Am J Cancer Res"},{"key":"2026070813374605800_aqag080-B8","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11; 14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"2026070813374605800_aqag080-B9","doi-asserted-by":"publisher","first-page":"5434","DOI":"10.1158\/1078-0432.CCR-16-0867","article-title":"Gene expression profiles in myeloma: ready for the real world?","volume":"22","author":"Szalat","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026070813374605800_aqag080-B10","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","article-title":"Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes","volume":"56","author":"Skerget","year":"2024","journal-title":"Nat Genet"},{"key":"2026070813374605800_aqag080-B11","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1097\/PAS.0000000000002421","article-title":"Comparison of immunohistochemistry with fluorescence in situ hybridization for assessment of CCND1 rearrangement in plasma cell myeloma","volume":"49","author":"Chen","year":"2025","journal-title":"Am J Surg Pathol"},{"key":"2026070813374605800_aqag080-B12","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026070813374605800_aqag080-B13","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2002-08-2436","article-title":"Translocation t(11; 14)(q13; q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants","volume":"101","author":"Avet-Loiseau","year":"2003","journal-title":"Blood"},{"key":"2026070813374605800_aqag080-B14","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41375-020-01060-w","article-title":"Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN)","volume":"35","author":"Liu","year":"2021","journal-title":"Leukemia"},{"key":"2026070813374605800_aqag080-B15","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1158\/1078-0432.CCR-04-1489","article-title":"Genetic abnormalities and patterns of antigenic expression in multiple myeloma","volume":"11","author":"Mateo","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2026070813374605800_aqag080-B16","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"2026070813374605800_aqag080-B17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/nrm.2016.27","article-title":"Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases","volume":"17","author":"Hydbring","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2026070813374605800_aqag080-B18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1309\/AJCPUS3PRRT5ZXVS","article-title":"Clinical, immunophenotypic, and genetic characterization of small lymphocyte-like plasma cell myeloma: a potential mimic of mature B-cell lymphoma","volume":"133","author":"Heerema-McKenney","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"2026070813374605800_aqag080-B19","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1111\/cas.15073","article-title":"Multiple myeloma with t(11; 14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence","volume":"112","author":"Kitadate","year":"2021","journal-title":"Cancer Sci"},{"key":"2026070813374605800_aqag080-B20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/(SICI)1096-9896(199806)185:2&lt;159::AID-PATH73&gt;3.0.CO","article-title":"Cyclin D3 expression in normal, reactive and neoplastic tissues","volume":"185","author":"Doglioni","year":"1998","journal-title":"J Pathol"},{"key":"2026070813374605800_aqag080-B21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.0105-2896.2006.00362.x","article-title":"Microarray-based understanding of normal and malignant plasma cells","volume":"210","author":"De Vos","year":"2006","journal-title":"Immunol Rev"},{"key":"2026070813374605800_aqag080-B22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1046\/j.1365-2141.2003.04577.x","article-title":"Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities","volume":"123","author":"Rasmussen","year":"2003","journal-title":"Br J Haematol"},{"key":"2026070813374605800_aqag080-B23","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/cr.2010.55","article-title":"Requirement for cyclin D3 in germinal center formation and function","volume":"20","author":"Peled","year":"2010","journal-title":"Cell Res"},{"key":"2026070813374605800_aqag080-B24","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1182\/blood.V90.8.3154","article-title":"Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of cyclin D3 and is not related to the proliferative activity","volume":"90","author":"Ott","year":"1997","journal-title":"Blood"},{"key":"2026070813374605800_aqag080-B25","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/(sici)1097-0215(19990517)81:4&lt;543::aid-ijc7&gt;3.0.co","article-title":"Expression of cyclin D2 and D3 in lymphoid lesions","volume":"81","author":"Teramoto","year":"1999","journal-title":"Int J Cancer"},{"key":"2026070813374605800_aqag080-B26","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12185-009-0382-6","article-title":"Bone marrow large B cell lymphoma bearing cyclin D3 expression: clinical, morphologic, immunophenotypic, and genotypic analyses of seven patients","volume":"90","author":"Watanuki","year":"2009","journal-title":"Int J Hematol"},{"key":"2026070813374605800_aqag080-B27","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1182\/blood-2018-07-862151","article-title":"CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1\u2013mantle cell lymphoma","volume":"133","author":"Mart\u00edn-Garcia","year":"2019","journal-title":"Blood"},{"key":"2026070813374605800_aqag080-B28","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1182\/blood-2016-11-751024","article-title":"Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations","volume":"129","author":"Curiel-Olmo","year":"2017","journal-title":"Blood"},{"key":"2026070813374605800_aqag080-B29","doi-asserted-by":"publisher","first-page":"1611375","DOI":"10.3389\/pore.2023.1611375","article-title":"Effective venetoclax-based treatment in relapsed\/refractory multiple myeloma patients with translocation t(6; 14)","volume":"29","author":"Cegl\u00e9di","year":"2023","journal-title":"Pathol Oncol Res"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/166\/1\/aqag080\/68721590\/aqag080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/166\/1\/aqag080\/68721590\/aqag080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:37:54Z","timestamp":1783532274000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/doi\/10.1093\/ajcp\/aqag080\/8728473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7,6]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqag080","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7]]},"article-number":"aqag080"}}